Skip to Content

Symdeko (ivacaftor / tezacaftor) and Alcohol / Food Interactions

There is 1 alcohol/food/lifestyle interaction with Symdeko (ivacaftor / tezacaftor):


ivacaftor ↔ food

Moderate Food Interaction

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ivacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.

ADJUST DOSING INTERVAL: According to the manufacturer, systemic exposure to ivacaftor increased approximately 2.5- to 4-fold and systemic exposure to lumacaftor increased approximately 2-fold following administration with fat-containing foods relative to administration in a fasting state. Tezacaftor exposure is not affected by administration of fat-containing foods.

MANAGEMENT: Patients treated with ivacaftor should avoid consumption of grapefruit juice and any food that contains grapefruit or Seville oranges. Ivacaftor, lumacaftor/ivacaftor, and tezacaftor/ivacaftor should all be administered with fat-containing foods such as eggs, avocados, nuts, butter, peanut butter, cheese pizza, and whole-milk dairy products. A typical cystic fibrosis diet will satisfy this requirement.


  1. "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
  2. "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
  3. "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.

Symdeko (ivacaftor / tezacaftor) drug interactions

There are 426 drug interactions with Symdeko (ivacaftor / tezacaftor)

Symdeko (ivacaftor / tezacaftor) disease interactions

There are 3 disease interactions with Symdeko (ivacaftor / tezacaftor) which include:

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.